Compare AbbVie Inc (ABBV) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Boston Beer Company Inc — how do they compare? AbbVie Inc trades at $254.18 (market cap $449.91B), while Boston Beer Company Inc trades at $179.9 (market cap $1.91B). The key difference: AbbVie Inc is far larger — about 235.6× Boston Beer Company Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| ABBV | SAM | |
|---|---|---|
Market Cap | $449.91B | $1.91B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $260.05 |
52-Week Low | $184.85 | $161.08 |
Enterprise Value | $513.38B | $1.78B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Boston Beer (SAM) trades at $183.16, down 0.25% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but negative net income margin of -3.15% and ROE of -7.75%. Recent Q1 2026 earnings missed expectations, though Q3 and Q4 2025 beat estimates. Cash flow improved to $11.56M net in 2025 after a negative 2024. Analyst consensus price target is $233.40 with 74% hold ratings.
SAM faces headwinds from declining volume growth and brand pressure, but maintains strong gross margins at 48.7%. The 27% upside to consensus target offers potential, though execution risks and competitive beverage market pose challenges. Institutional sentiment is cautious with limited buy ratings despite positive cash flow recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
